Pan American Oncology Trials, Llc

Rio Piedras 935

1 studies enrolling now · 6 studies all time

What they study most

Gastric, or Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Homologous Recombination Deficiency (HRD), Marginal Zone Lymphoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Gastric Adenocarcinoma, Relapsed/Refractory Follicular Lymphoma, Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer, Waldenstrom Macroglobulinemia

Studies at this site

• Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia — Recruiting now
• A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma — Recruiting now
• A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma — Running, not enrolling
• A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer — Running, not enrolling
• Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma — Completed
• Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency — Stopped early